Comparison of COVID-19 and Influenza-Related Outcomes in the United States during Fall–Winter 2022–2023: A Cross-Sectional Retrospective Study

Author:

Kopel Hagit1,Bogdanov Alina2,Winer-Jones Jessamine P.2ORCID,Adams Christopher2,Winer Isabelle H.2,Bonafede Machaon2,Nguyen Van Hung3,Mansi James A.1ORCID

Affiliation:

1. Moderna, Inc., Cambridge, MA 02139, USA

2. Veradigm, Chicago, IL 60654, USA

3. VHN Consulting Inc., Montreal, QC H2V 3L8, Canada

Abstract

Influenza and COVID-19 contribute significantly to the infectious disease burden during the respiratory season, but their relative burden remains unknown. This study characterizes the frequency and severity of medically attended COVID-19 and influenza during the peak of the 2022–2023 influenza season in the pediatric, adult, and older adult populations and characterizes the prevalence of underlying conditions among patients hospitalized with COVID-19. This cross-sectional analysis included individuals in the Veradigm EHR Database linked to Komodo claims data with a medical encounter between 1 October 2022 and 31 March 2023 (study period). Patients with medical encounters were identified with a diagnosis of COVID-19 or influenza during the study period and stratified based on the highest level of care received with that diagnosis. Among 23,526,196 individuals, there were more COVID-19-related medical encounters than influenza-related encounters, overall and by outcome. Hospitalizations with COVID-19 were more common than hospitalizations with influenza overall (incidence ratio = 4.6) and in all age groups. Nearly all adults hospitalized with COVID-19 had at least one underlying medical condition, but 37.1% of 0–5-year-olds and 25.0% of 6–17-year-olds had no underlying medical conditions. COVID-19 was associated greater burden than influenza during the peak of the 2022–2023 influenza season.

Funder

Moderna Inc.

Publisher

MDPI AG

Subject

General Medicine

Reference43 articles.

1. A new coronavirus associated with human respiratory disease in China;Wu;Nature,2020

2. The emergence, genomic diversity and global spread of SARS-CoV-2;Li;Nature,2021

3. The evolution of SARS-CoV-2;Markov;Nat. Rev. Microbiol.,2023

4. (2023, September 02). Epic Research. Respiratory Illnesses. Epic Research. Available online: https://epicresearch.org/data-tracker/respiratory-illnesses.

5. Risk factors for SARS-CoV-2 infection and transmission in households with children with asthma and allergy: A prospective surveillance study;Seibold;J. Allergy Clin. Immunol.,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3